SG11201809822SA - Atropine-containing aqueous composition - Google Patents

Atropine-containing aqueous composition

Info

Publication number
SG11201809822SA
SG11201809822SA SG11201809822SA SG11201809822SA SG11201809822SA SG 11201809822S A SG11201809822S A SG 11201809822SA SG 11201809822S A SG11201809822S A SG 11201809822SA SG 11201809822S A SG11201809822S A SG 11201809822SA SG 11201809822S A SG11201809822S A SG 11201809822SA
Authority
SG
Singapore
Prior art keywords
shi
buffer
cho
international
takayama
Prior art date
Application number
SG11201809822SA
Other languages
English (en)
Inventor
Donald Tan
Roger Beuerman
Hiroyuki Asada
Kyohei Takahashi
Koji Sakanaka
Takashi Morimoto
Toyomi Fujisawa
Original Assignee
Singapore Health Serv Pte Ltd
Univ Nanyang Tech
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60411416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201809822S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Singapore Health Serv Pte Ltd, Univ Nanyang Tech, Santen Pharmaceutical Co Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11201809822SA publication Critical patent/SG11201809822SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
SG11201809822SA 2016-05-25 2017-05-24 Atropine-containing aqueous composition SG11201809822SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201604200P 2016-05-25
PCT/JP2017/019423 WO2017204262A1 (en) 2016-05-25 2017-05-24 Atropine-containing aqueous composition

Publications (1)

Publication Number Publication Date
SG11201809822SA true SG11201809822SA (en) 2018-12-28

Family

ID=60411416

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809822SA SG11201809822SA (en) 2016-05-25 2017-05-24 Atropine-containing aqueous composition

Country Status (15)

Country Link
US (3) US20210267885A1 (enExample)
EP (2) EP3463360B2 (enExample)
JP (6) JP6590860B2 (enExample)
KR (4) KR102804061B1 (enExample)
CN (3) CN117205210A (enExample)
AR (1) AR108591A1 (enExample)
CA (1) CA3023149C (enExample)
EA (1) EA201892703A1 (enExample)
ES (1) ES2929368T3 (enExample)
MY (1) MY189774A (enExample)
PH (1) PH12018502421A1 (enExample)
SG (1) SG11201809822SA (enExample)
TW (3) TWI849355B (enExample)
UA (1) UA126195C2 (enExample)
WO (1) WO2017204262A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
EP3585386A4 (en) 2017-02-21 2020-12-30 Singapore Health Services PTE Ltd COMPOSITION AND PROCESS FOR PREVENTING OR DELAYING THE ONCE OF MYOPIA INCLUDING ATROPINE
EP3970694A1 (en) 2017-05-11 2022-03-23 Vyluma Inc. Atropine pharmaceutical compositions
CN110934869B (zh) * 2018-09-25 2023-07-04 沈阳兴齐眼药股份有限公司 一种阿托品药物组合物和药盒产品
CN114533652B (zh) * 2018-09-25 2024-12-13 沈阳兴齐眼药股份有限公司 药物组合物、其制备方法和用途
MA52857A (fr) 2019-03-01 2021-04-21 Medivis S R L Formulations ophtalmiques à base d'atropine
CA3189821A1 (en) 2020-08-04 2022-02-10 Santen Pharmaceutical Co., Ltd. Agent for treating myopia, preventing myopia and/or suppressing myopia progression
KR20230087514A (ko) * 2020-10-14 2023-06-16 산텐 세이야꾸 가부시키가이샤 안정한 의약 조성물
PE20231656A1 (es) 2020-11-02 2023-10-17 Trethera Corp Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
WO2022130337A1 (en) * 2020-12-17 2022-06-23 Sun Pharmaceutical Industries Limited An aqueous sterile solution of atropine for ophthalmic use
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
US20230120997A1 (en) * 2021-10-18 2023-04-20 Ocular Science, Inc. Compositions and methods for myopia control and orthokeratology lenses treatment
CN114129511A (zh) * 2021-12-07 2022-03-04 河南润弘制药股份有限公司 一种具有改进稳定性的硫酸阿托品注射液
JP7884090B2 (ja) * 2022-09-11 2026-07-02 アルコン インク． ベンジルアトロピンを含む水性医薬組成物及びその使用
WO2025018419A1 (ja) 2023-07-20 2025-01-23 センジュ ユーエスエー、インコーポレイテッド 水性液剤
JP7665073B1 (ja) 2024-04-05 2025-04-18 ロート製薬株式会社 容器に収容してなる眼科用組成物
JP7723851B1 (ja) 2024-11-22 2025-08-14 参天製薬株式会社 アトロピン含有水性医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
JP3166002B2 (ja) * 1997-01-27 2001-05-14 日本車輌製造株式会社 自動車の洗浄装置
US20030096831A1 (en) 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
CN1509172A (zh) * 2001-05-25 2004-06-30 ά����ҩ��˾ 哌仑西平眼用凝胶剂
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
JP2010528010A (ja) * 2007-05-21 2010-08-19 ニューロプティックス コーポレイション アミロイドβ造影剤の眼用製剤およびその使用の方法
CN101327216A (zh) * 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
CN104983739B (zh) * 2015-06-25 2018-01-16 成都乾坤动物药业股份有限公司 一种多功能药物组合及其制备方法和应用
JP2017102939A (ja) * 2016-12-26 2017-06-08 株式会社プロフィールド オーサリング装置、オーサリング方法、およびプログラム
EP3970694A1 (en) * 2017-05-11 2022-03-23 Vyluma Inc. Atropine pharmaceutical compositions

Also Published As

Publication number Publication date
KR102804061B1 (ko) 2025-05-07
JP2018021007A (ja) 2018-02-08
EA201892703A1 (ru) 2019-04-30
KR20230141882A (ko) 2023-10-10
JP2023058574A (ja) 2023-04-25
CA3023149C (en) 2024-07-02
EP3463360B1 (en) 2022-08-31
KR20220154842A (ko) 2022-11-22
CN117205209A (zh) 2023-12-12
TW201808289A (zh) 2018-03-16
JP2020007356A (ja) 2020-01-16
JP2025084921A (ja) 2025-06-03
JP2021120404A (ja) 2021-08-19
KR102580933B1 (ko) 2023-09-19
TW202206070A (zh) 2022-02-16
UA126195C2 (uk) 2022-08-31
KR20250067951A (ko) 2025-05-15
JP7224390B2 (ja) 2023-02-17
JP2025176149A (ja) 2025-12-03
EP3463360B2 (en) 2026-07-15
TWI791438B (zh) 2023-02-11
WO2017204262A1 (en) 2017-11-30
PH12018502421A1 (en) 2019-09-30
EP4112055A1 (en) 2023-01-04
JP6886502B2 (ja) 2021-06-16
US20210267885A1 (en) 2021-09-02
MY189774A (en) 2022-03-04
CA3023149A1 (en) 2017-11-30
CN109310687B (zh) 2023-10-20
TW202325296A (zh) 2023-07-01
EP3463360A1 (en) 2019-04-10
CN117205210A (zh) 2023-12-12
AR108591A1 (es) 2018-09-05
TWI849355B (zh) 2024-07-21
ES2929368T3 (es) 2022-11-28
EP3463360A4 (en) 2020-01-29
US20260183235A1 (en) 2026-07-02
KR20190013877A (ko) 2019-02-11
US20240307305A1 (en) 2024-09-19
JP6590860B2 (ja) 2019-10-16
TWI874894B (zh) 2025-03-01
CN109310687A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
SG11201906222WA (en) Jak1 selective inhibitors
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201900883UA (en) Combination treatment for hematological cancers
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201902949PA (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201809031XA (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
SG11201908052PA (en) Lipid-based nanoparticles with enhanced stability
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201807023QA (en) Compositions and methods for preventing and/or treating vitamin b12 deficiency
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries